Percent reduction in disease incidence in a vaccinated group compared with an unvaccinated or comparative vaccine group under optimal conditions
Usually measured in randomized controlled clinical trials
Ability of vaccine to prevent disease in real world community conditions1
Usually done with little control of who gets vaccinated, setting, and reason for vaccination. These are considered observational studies.1 For methodological reasons, effectiveness estimates are expected to be lower than efficacy estimates2
The effectiveness of FLUMIST QUADRIVALENT is based on data demonstrating3
Public Health England (PHE) 2017/2018 End of Influenza Season Vaccine Effectiveness (VE) Data4*
PHE exists to protect and improve health and well-being and reduce health inequalities within the United Kingdom (UK)5
*Adjusted for age group, risk group, sex, month, pilot area, and surveillance scheme. Influenza VE was measured from October 2017 to mid-April 2018 using a test-negative case control design across 5 primary care influenza sentinel swabbing schemes in England (two schemes), Scotland, Wales, and Northern Ireland.4
†Most prevalent strain circulating in the UK during the 2017/2018 influenza season.7
FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.
You may report side effects related to AstraZeneca products by clicking here.